Stiris Research Inc Announces First Site Initiation Visit in Phase III Glioblastoma Trial
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the successful initiation of our first site in the Phase III Glioblastoma (GBM) study we are conducting.
“Stiris Research is excited to announce, that on February 22nd, 2024, we initiated our first site in the Phase III Glioblastoma (GBM) trial. This was an important milestone on the study and one step closer to bringing a new treatment to patients with recurrent glioblastoma.” said Shantal Feltham, President & CEO.
Glioblastoma (GBM), also referred to as a grade IV astrocytoma, is a fast-growing and aggressive brain tumor. It invades the nearby brain tissue, but generally does not spread to distant organs. In adults, GBM occurs most often in the cerebral hemispheres, especially in the frontal and temporal lobes of the brain. GBM is a devastating brain cancer that can result in death in six months or less, if untreated. (https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme)
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: